Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting
270 studies found for:    "Cytomegalic inclusion disease"
Show Display Options
Rank Status Study
1 Unknown  Certican® (Everolimus) Against Cytomegalovirus Disease in Renal Transplant Patients
Condition: Cytomegalovirus Disease
Interventions: Drug: Certican (everolimus) + valganciclovir;   Drug: Valganciclovir
2 Completed Cytogam Administration in Abdominal Organ Transplant Recipients at High Risk for Cytomegalovirus Infection
Condition: Cytomegalovirus Disease
Interventions: Drug: Valganciclovir;   Biological: CMV hyperimmune globulin
3 Completed A Study of MCMV5322A/MCMV3068A for the Prevention of Cytomegalovirus Disease in High-Risk Kidney Allograft Recipients
Condition: Cytomegalovirus Infections
Interventions: Drug: MCMV3068A;   Drug: MCMV5322A;   Drug: Placebo
4 Active, not recruiting SUSTAIN: A Randomized, Double-Blind, Multicenter, Phase 3 Study of the Efficacy, Safety, and Tolerability of Brincidofovir Versus Valganciclovir for the Prevention of Cytomegalovirus Disease in CMV Seronegative Kidney Allograft Recipients
Condition: Cytomegalovirus Disease
Interventions: Drug: Brincidofovir;   Drug: Valganciclovir
5 Enrolling by invitation Screening for Congenital Cytomegalovirus Infection in Newborns
Condition: Cytomegalovirus Infections
Intervention: Other: Observation
6 Completed Quantiferon - Cytomegalovirus (CMV) and the Prediction of CMV Infection In High Risk Solid Organ Transplant Recipients
Condition: Cytomegalovirus Infection
Intervention:
7 Recruiting Evaluation of the PK and PD of Ganciclovir in Premature Infants Receiving Treatment for CMV Infection
Condition: Cytomegalovirus Infections
Intervention:
8 Completed
Has Results
Short-Term vs. Long-Term Valganciclovir Therapy for Symptomatic Congenital CMV Infections
Condition: Cytomegalovirus Infection
Interventions: Other: Placebo;   Drug: Valganciclovir
9 Completed Efficacy Study of Human Cytomegalovirus (HCMV) Hyperimmune Globulin to Prevent Congenital HCMV Infection
Condition: Cytomegalovirus Infection
Interventions: Drug: HCMV-specific hyperimmune globulin (Cytotect®);   Drug: Isotonic solution of sodium chloride (placebo)
10 Active, not recruiting A French Cohort of Transplant Recipients With CMV Infection : Risk Factors for Antiviral Resistance in the Prophylaxis Era.
Condition: Transplant Recipients With CMV Infection
Intervention: Biological: CMV Infection
11 Completed gB/MF59 Vaccine in Preventing Cytomegalovirus Infection in Healthy Adolescent Females
Condition: Cytomegalovirus Infections
Interventions: Biological: MF-59;   Drug: Placebo;   Biological: CMV gB vaccine
12 Completed
Has Results
Maribavir for Treatment of Resistant or Refractory CMV Infections in Transplant Recipients
Condition: Cytomegalovirus Infections
Intervention: Drug: Maribavir
13 Completed Valganciclovir for Treatment of Cytomegalovirus Infection in Solid Organ Transplant Patients
Condition: Cytomegalovirus Infection
Intervention: Drug: Single arm (ganciclovir and valganciclovir)
14 Terminated Trial of Preemptive Treatment With Oral Valganciclovir Compared With Intravenous (IV) Ganciclovir for Cytomegalovirus Infection After Bone Marrow or Peripheral Blood Stem Cell Transplant
Condition: Cytomegalovirus Infections
Interventions: Drug: Valganciclovir;   Drug: Ganciclovir
15 Recruiting Analysis of CMV Infections in Patients With Brain Tumors or Brain Metastases During and After Radio(Chemo)Therapy
Condition: Cytomegalovirus Infections
Intervention: Other: Blood draw and MRI
16 Recruiting Conversion to Sirolimus: Effects in Cytomegalovirus Infection Recurrence
Condition: Cytomegalovirus Infections
Interventions: Drug: Drug conversion to sirolimus;   Drug: Maintenance of the current regimen
17 Completed Phase I/II Study of Human Anti-Cytomegalovirus (CMV) Monoclonal Antibody MSL-109 in Newborns With Symptomatic Congenital CMV Infection Without Central Nervous System Disease
Condition: Cytomegalovirus Infections
Intervention: Drug: SDZ MSL-109
18 Completed Clinical Evaluation of Ultrashort-term Heat Inactivation of Cytomegalovirus (CMV) Containing Raw Breast Milk to Prevent CMV-infection of Preterm Infants
Conditions: Cytomegalovirus Infection;   Preterm Infants
Intervention: Procedure: ultrashort heat inactivation
19 Completed A Pharmacokinetic and Tolerance Study of Oral Ganciclovir in HIV-Infected Children With Asymptomatic Cytomegalovirus Infection and Low CD4 Cell Counts or Quiescent Cytomegalovirus Disease
Conditions: Cytomegalovirus Infections;   HIV Infections
Intervention: Drug: Ganciclovir
20 Completed
Has Results
IMPACT Study: A Study of Valcyte (Valganciclovir) for Prevention of Cytomegalovirus Disease (CMV) in Kidney Allograft Recipients
Condition: Cytomegalovirus Infections
Intervention: Drug: Valganciclovir

   Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results    Last Page
Study has passed its completion date and status has not been verified in more than two years.